2-氯嘧啶-5-硼酸 | 1003845-06-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯嘧啶-5-硼酸
• 中文别名: 2-氯-5-嘧啶硼酸
• 英文名称: (2-chloropyrimidin-5-yl)boronic acid
• 英文别名: 2-chloropyrimidine-5-boronic acid
• CAS: 1003845-06-4
• 化学式: C₄H₄BClN₂O₂
• mdl: MFCD08063113
• 分子量: 158.352
• InChiKey: YTCIHPTZKKWKKC-UHFFFAOYSA-N

物化性质

• 沸点：
  425.4±37.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.38
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存储条件：2-8°C，避光，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloropyrimidine-5-boronic acid
Synonyms: 2-Chloropyrimidin-5-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloropyrimidine-5-boronic acid
CAS number: 1003845-06-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H4BClN2O2
Molecular weight: 158.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯嘧啶-5-硼酸 在 N-氯代丁二酰亚胺 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以75%的产率得到2,5-二氯嘧啶
  参考文献：
  名称：

  NOVEL COMPOUNDS AS GPR119 AGONISTS

  摘要：

  本发明涉及式(I)的新化合物作为GPR119激动剂，包含此类化合物的组合物及其制备方法。

  公开号：

  US20170291910A1
• 作为产物：
  描述：

  5-溴-2-氯嘧啶 在 正丁基锂 、 硼酸三异丙酯 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 4.0h， 以70%的产率得到2-氯嘧啶-5-硼酸
  参考文献：
  名称：

  嘧啶硼酸的双铃木交叉偶联反应：新型多功能介电体的合成

  摘要：

  铃木双交叉偶联反应已成功地用于合成具有两个反应性氯基和从2开始的烷氧基侧链的5,5'-（5-丁氧基-1,3-亚苯基）双（2-氯嘧啶）氯嘧啶-5基硼酸和1,3-二溴-5-丁氧基苯。通过分别与苯胺和苯酚，氮和氧亲核试剂反应来测试该介电试剂的反应性。新的介电体将进一步为构建大型杂原子桥接的大环化合物提供理想的平台，以实现超分子和材料化学中所需的特性和功能。版权所有©2012 John Wiley＆Sons，Ltd.

  DOI：

  10.1002/aoc.2865

文献信息

• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：PROPELLON THERAPEUTICS INC

  公开号：WO2019046944A1

  公开（公告）日：2019-03-14

  The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：(I) 包括这些化合物的组合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、紊乱或状况的药物。
• [EN] MACROCYLIC PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDINE MACROCYCLIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015150557A1

  公开（公告）日：2015-10-08

  The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）的取代大环嘧啶衍生物，其中变量的含义如权利要求中所定义。根据本发明的化合物具有EF2K抑制活性，还可能具有Vps34抑制活性。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。
• [EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
  申请人：ABBVIE INC

  公开号：WO2016168641A1

  公开（公告）日：2016-10-20

  The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

  这项发明提供了三环杂环化合物，其药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
• [EN] FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET DE PYRAZOLE CONDENSÉS COMME MODULATEURS DE L'ACTIVITÉ DU TNF
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2015086512A1

  公开（公告）日：2015-06-18

  A series of substituted benzimidazole, imidazo[1,2-α]pyridine and pyrazolo[1,5- α]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列取代苯并咪唑、咪唑并[1,2-α]吡啶和吡唑并[1,5-α]吡啶衍生物及其类似物，作为人类TNFα活性的有效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经学和神经退行性疾病；疼痛和伤害感知性疾病；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• Catalytic C–C coupling of diazo compounds with arylboronic acids: using surface modified sewage sludge as catalyst
  作者：Zhipeng Zhang、Yang Yu、Yuxing Xie、Timothy Hughes、Jun Xu、Fei Huang、He Huang

  DOI：10.1039/d0gc00317d

  日期：——

  carbonaceous materials (SW) by perchloric acid catalyzed coupling reactions between diazo compounds and arylboronic acids was developed. The reaction shows a high level of functional tolerance and a broad substrate scope. Furthermore, the highly selective 1,2-alkyl shift products were furnished through the sterically demanding R4, R5 migration of diazo compounds (3-diazochromanone). The structures of 1,2-shift

  通过高氯酸催化重氮化合物与芳基硼酸之间的偶联反应，开发了一种绿色，温和且高效的合成方法，该方法利用污水污泥衍生的碳质材料（SW）合成二芳基次甲基。该反应显示出高水平的功能耐受性和广泛的底物范围。此外，通过空间要求高的R 4，R 5提供了高选择性的1,2-烷基转移产物重氮化合物（3-重氮苯并二氢吡喃酮）的迁移。通过单晶X射线分析进一步证实了1，2-移位产物的结构。值得注意的是，darifenacin（一种用于膀胱过度活动症的临床药物，OAB）和diclofensine（一种显示出抗抑郁和单胺再摄取抑制剂活性的兴奋剂）的核心结构的合成进一步证明了该方法的有效性和合成潜力。

表征谱图